Century Therapeutics (IPSC) Total Current Liabilities (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Total Current Liabilities data on file, last reported at $13.6 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $13.6 million, down 6.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.6 million (down 6.46% YoY), and the FY2025 annual result was $20.2 million, down 84.42% from the prior year.
• Total Current Liabilities declined to $13.6 million in Q1 2026 per IPSC's latest filing, from $20.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $129.8 million in Q4 2024 and troughed at $13.6 million in Q1 2026.
• A 5-year average of $26.8 million and a median of $20.2 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities soared 627.23% in 2024, then tumbled 84.42% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $29.8 million in 2022, then sank by 40.15% to $17.8 million in 2023, then soared by 627.23% to $129.8 million in 2024, then plunged by 84.42% to $20.2 million in 2025, then plunged by 32.93% to $13.6 million in 2026.
• Business Quant data shows IPSC's Total Current Liabilities at $13.6 million in Q1 2026, $20.2 million in Q4 2025, and $22.0 million in Q3 2025.